TipRanks
Go Ultimate55% OFF

Compare Pharmaust Limited (ECQ0) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:ECQ0Pharmaust LimitedEUR 0.05EUR 42.86M-4.91-34.29%Moderate BuyUnlock the DE:ECQ0 analyst price target with TipRanks PremiumDE:ECQ0Unlock the DE:ECQ0 top-analyst price target with TipRanks Premium
AU:PARParadigm BiopharmaceuticalsAUD 0.25AUD 153.48M-1.61-43.68%Moderate BuyUnlock the AU:PAR analyst price target with TipRanks PremiumDE:ECQ0 vs AU:PARUnlock the AU:PAR top-analyst price target with TipRanks Premium
AU:IMMImmutep LtdAUD 0.02AUD 33.90M-0.43-91.93%Moderate BuyUnlock the AU:IMM analyst price target with TipRanks PremiumDE:ECQ0 vs AU:IMMUnlock the AU:IMM top-analyst price target with TipRanks Premium
AU:PTXPrescient Therapeutics LimitedAUD 0.05AUD 60.62M-7.688.16%―Unlock the AU:PTX analyst price target with TipRanks PremiumDE:ECQ0 vs AU:PTXUnlock the AU:PTX top-analyst price target with TipRanks Premium
AU:BOTBotanix Pharmaceuticals LimitedAUD 0.01AUD 27.63M-0.31-92.59%Moderate BuyUnlock the AU:BOT analyst price target with TipRanks PremiumDE:ECQ0 vs AU:BOTUnlock the AU:BOT top-analyst price target with TipRanks Premium
AU:RCERecce Pharmaceuticals Ltd.AUD 0.36AUD 110.10M-6.95-12.20%―Unlock the AU:RCE analyst price target with TipRanks PremiumDE:ECQ0 vs AU:RCEUnlock the AU:RCE top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:ECQ0Pharmaust Limited0.05-0.01-22.03%
AU:PARParadigm Biopharmaceuticals0.24-0.15-37.97%
AU:IMMImmutep Ltd0.02-0.26-91.79%
AU:PTXPrescient Therapeutics Limited0.050.0115.22%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.12-92.31%
AU:RCERecce Pharmaceuticals Ltd.0.36-0.04-10.00%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts